Working to deliver functional improvement for people living with Duchenne muscular dystrophy

There is a significant unmet need for new treatment options that deliver functional improvement for boys and adolescents living with Duchenne muscular dystrophy. Encouraging results have been seen in DELIVER, the global clinical trial of zeleciment rostudirsen (z-rostudirsen).

The FORZETTO trial, sponsored by Dyne Therapeutics, Inc., is designed to confirm the results from the DELIVER trial. FORZETTO will collect information from participants as they receive z- rostudirsen. In addition to learning how z- rostudirsen may affect participant's skeletal and heart muscles, Dyne Therapeutics is also interested to learn how z- rostudirsen may affect the quality of life of participants and their caregivers.

How long is this study?

Participation in the study could last a little over 3 years. However, being in this study is completely voluntary. Participants can leave at any time. Leaving the study will not affect the quality of the health care participants receive.

Who can participate in the FORZETTO study?

Eligible Participants must:

- Be Males with Duchenne muscular dystrophy and a mutation amenable to exon 51 skipping
- Be 4 to 18 years old (can be 18)
- Be ambulatory
- Have the ability to complete a clinical assessment called "Rise from floor" (RFF) in under 10 seconds
- Currently be receiving a steroid medicine

Note: Additional criteria apply

Are there costs for participating?

Study treatment and all study tests and procedures are provided at no cost to study participants and their parents or caregivers. Participants will be reimbursed for approved study-related travel expenses. Concierge services will be available to participants who choose to have study-related travel arranged for them at no cost.

For more information

Email: clinicaltrials@dyne-tx.com

Dyne Web:
Clinical Trials - Dyne Therapeutics

ClinicalTrials.Gov: